The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 3 , Pages 620-626.e3, March 2008

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients

  • Raja M. Flores, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationAddress for reprints: Raja M. Flores, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-879, New York, NY 10021.
  • ,
  • Harvey I. Pass, MD

      Affiliations

    • Department of Cardiothoracic Surgery, New York University Medical Center, New York, NY
  • ,
  • Venkatraman E. Seshan, PhD

      Affiliations

    • Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Joseph Dycoco, BA

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Maureen Zakowski, MD

      Affiliations

    • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Michele Carbone, MD

      Affiliations

    • Department of Pathology, University of Hawaii, Honolulu, Hawaii
  • ,
  • Manjit S. Bains, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
  • ,
  • Valerie W. Rusch, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY

Received 3 May 2007; received in revised form 13 September 2007; accepted 22 October 2007. published online 15 February 2008.

Objective

The optimal procedure for resection of malignant pleural mesothelioma is controversial, partly because previous analyses include small numbers of patients. We performed a multi-institutional study to increase statistical power to detect significant differences in outcome between extrapleural pneumonectomy and pleurectomy/decortication.

Methods

Patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Survival and prognostic factors were analyzed by the Kaplan–Meier method, log-rank test, and Cox proportional hazards analysis.

Results

From 1990 to 2006, 663 consecutive patients (538 men and 125 women) underwent resection. The median age was 63 years (range, 26–93 years). The operative mortality was 7% for extrapleural pneumonectomy (n = 27/385) and 4% for pleurectomy/decortication (n = 13/278). Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P < .001), epithelioid versus non-epithelioid histology (P < .001), extrapleural pneumonectomy versus pleurectomy/decortication (P < .001), multimodality therapy versus surgery alone (P < .001), and gender (P < .001). Multivariate analysis demonstrated a hazard rate of 1.4 for extrapleural pneumonectomy (P < .001) controlling for stage, histology, gender, and multimodality therapy.

Conclusion

Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.

Abbreviations and Acronyms: EPP, extrapleural pneumonectomy, MPM, malignant pleural mesothelioma, P/D, pleurectomy/decortication

CTSNet classification: 10, 14

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was presented at the plenary session at the 2007 AATS Meeting.

 Dr Pass reports consulting fees from GlaxoSmithKline and Astra Zeneca.

PII: S0022-5223(07)01899-5

doi:10.1016/j.jtcvs.2007.10.054

The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 3 , Pages 620-626.e3, March 2008